|drug3190||Standar medical treatmen Wiki||0.71|
|drug2578||Plasma exchange Wiki||0.71|
|D003928||Diabetic Nephropathies NIH||0.71|
|D007674||Kidney Diseases NIH||0.21|
|D018352||Coronavirus Infections NIH||0.03|
There are 2 clinical trials
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Description: ESRD will be defined as need for chronic dialysis or renal transplantation.Measure: Time to ESRD or death Time: 5 to 9 years
Description: Quality of life as measured by the Kidney Disease Quality of Life Short Form (KDQoL-SF)Measure: Quality of life (KDQoL-SF) Time: 5 to 9 years
Description: Time until doubling of serum creatinineMeasure: Time until doubling of serum creatinine Time: 5 to 9 years
Description: The risk of a CHF hospitalization will be based on the participant-time data, specifically, the number of events per years.Measure: Incidence of congestive heart failure hospitalization (CHF) Time: 5 to 9 years
Description: The risk of a MACE event will be based on participant-time data, specifically, the number of events per participant years.Measure: Incidence of a three-point MACE Time: 5 to 9 years
Description: The risk of a PVD event will be based on participant-time data, specifically, the number of events per participant years.Measure: Incidence of a peripheral vascular disease (PVD) Time: 5 to 9 years
Description: Percentage of participants with 50% reduction in UACR from baselineMeasure: Percentage of participants with 50% reduction in UACR from baseline Time: 5 to 9 years
Description: Rate of change in eGFR per year during the study period.Measure: Rate of change in eGFR per year during the study period Time: 5 to 9 years
With potential antiviral effects on severe acute respiratory syndrome (SARS) and as a methyl-xanthine derived inhibitor of phosphodiesterase-4, pentoxifylline basically functions as a hemorrheologic agent for a better circulation and oxygenation and exerts unique effects on immune modulation, inflammation and oxidative stress. As the main regulator of cAMP metabolism, posphodiesterase-4 plays a key role in proinflammatory and immune cells. Pentoxifylline plays its anti-inflammatory role by reducing the production of proinflammatory cytokines such as TNF-a, IL-1 and IL-6. Given its unique impacts on immune modulation, homeostasis and fibrinolysis and its supportive effects on oxidative stress and organ failure, pentoxifylline can constitute a multipurpose and generally-safe adjuvant therapy for COVID-19 patients.
Description: Number of Participants need hospitalizationMeasure: Primary Outcome Time: 7 days
Description: Incidence of any acute respiratory infectionMeasure: Respiratory infection Time: 7 days
Description: Absolute and relative frequencies of Serious Adverse EventsMeasure: Serious Adverse Events Time: 7 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports